Evidence map›Paper›PMID 40453824›Full record

Article3 Biotech2025

Fabrication of

Lakshmanan Govindan, Prabhu Raju, Surendirakumar Kannaiah, Nivetha Arunprakash, Saud Alqahtani, Kumarappan Chidambaram

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lakshmanan GovindanSri Lakshmi Narayana Institute of Medical Sciences (Affiliated to Bharath Institute of Higher Education and Research), Puducherry, 605 502 India.
Prabhu RajuDepartment of Biotechnology, JJ College of Arts and Science (Autonomous), (Affiliated to Bharathidasan University, Tiruchirappalli), Pudukkottai, 622 422 Tamilnadu India.
Surendirakumar KannaiahDepartment of Microbiology, JJ College of Arts and Science (Autonomous), (Affiliated to Bharathidasan University, Tiruchirappalli), Pudukkottai, 622 422 Tamilnadu India.ORCID 0000-0002-0237-4685
Nivetha ArunprakashDepartment of Chemistry, Holy Cross College (Autonomous), (Affiliated to Bharathidasan University, Tiruchirappalli), Tiruchirappalli, 620 002 Tamilnadu India.
Saud AlqahtaniDepartment of Pharmacology, College of Pharmacy, King Khalid University, Abha, 61421 Saudi Arabia.
Kumarappan ChidambaramDepartment of Pharmacology, College of Pharmacy, King Khalid University, Abha, 61421 Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medicinal plant-based biocompatible nanomaterials have become increasingly important in the healthcare field. Zeolitic imidazole (ZIF-8) frameworks are fascinating porous crystalline materials that have great attention in the field of drug delivery due to their biodegradability, pH sensitivity to changes in acidic conditions, and chemical durability. The development of ZIF-8 particles loaded with

Indexed as

Achyranthes aspera (AA)Anticancer activityBiocompatibilityMedicinal PlantsZeolitic imidazole frameworks (ZIFs)

Identifiers

PMID40453824
PMCPMC12119453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.